Incyte (NASDAQ:INCY) said it would end a phase 3 program examining its myelofibrosis candidate parsaclisib with Jakafi (ruxolitinib) after an interim analysis showed the study was unlikely to meet its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback